Fosun International reports 160.3% increase in interim profit

Fosun International reported its 2026 interim results, highlighting a significant recovery in profitability. The group's total revenue reached RMB 86.96 billion, while profit attributable to shareholders rose by 160.3% year-on-year to RMB 1.72 billion. Overseas revenue accounted for 56.5% of the total, reaching RMB 49.16 billion.

Chairman Guo Guangchang noted that the results reflect recent strategic adjustments aimed at stabilizing the company's growth trajectory. The group's core business segments—including Fosun Pharma, Yuyuan Inc., Fosun Life (Portugal), and Fosun Tourism—contributed 73.5% of total revenue. Management emphasized the successful integration of the insurance and core industrial sectors to enhance future profitability.

To drive innovation, Fosun invested RMB 4.2 billion in scientific and technological research during the first half of the year, a 16.7% increase. The company is focusing on globalizing its operations, particularly in the healthcare sector, by building comprehensive R&D pipelines and strengthening its international commercialization capabilities.